A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Terminated · Phase 3 · NCT06400511
Conditions: Blepharitis
At a glance
- Research payments reported, 2025
- $3.7M
- U.S. investigators named
- 26
- Sites paid
- 26
- Planned or actual enrollment
- 477
About the trial
- Sponsor
- Famy Life Sciences, a Viatris Company
- Tested
- Pimecrolimus 0.3% Ophthalmic Ointment (drug), Placebo Ophthalmic Ointment (drug)
- Dates
- Started 2024-04-22; completion 2025-10-15
- Results posted
- Not yet
The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.
From ClinicalTrials.gov, last updated 2026-01-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Oyster Point Pharma, Inc. reported $3.7M in research payments for this study in 2025 (280 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert H. Gross, MD Ophthalmology · Phoenix, AZ
- Jason Bacharach, MD Ophthalmology · Petaluma, CA
- Sherif M. El-harazi, MD MPH Ophthalmology · Glendale, CA
- Joseph R. Martel, MD Ophthalmology · Rancho Cordova, CA
- Ehsan Sadri, M.D. Ophthalmology · Newport Beach, CA
- Ryan Taban, M.D. Ophthalmology · Garden Grove, CA
- David L. Wirta, MD Ophthalmology · Newport Beach, CA
- Kaleb S. Abbott, OD Optometrists · Aurora, CO
- Benjamin K. Lambright, M.D. Ophthalmology · Lecanto, FL
- Don J. Perez, MD Ophthalmology · Tampa, FL
- Philip L. Shettle, D.O. Ophthalmology · Largo, FL
- Jennifer L. Kim, MD Ophthalmology · Morrow, GA
- William B. Lee, MD Ophthalmology · Atlanta, GA
- Shane R. Kannarr, OD Optometrists · Pittsburg, KS
- John C. Meyer, MD Ophthalmology · Louisville, KY
- Eugene E. Protzko, M.D. Ophthalmology · Havre De Grace, MD
- Gina M. Wesley, O.D. Optometrists · Medina, MN
- Michael S. Korenfeld, MD Ophthalmology · Washington, MO
- Anthony J. Verachtert, O.D. Optometrists · Kansas City, MO
- Carol A. Aune, OD Optometrists · Raleigh, NC
- Christopher M. Spearman, M.D. Ophthalmology · Cranberry Township, PA
- Gary W. Jerkins, MD Ophthalmology · Nashville, TN
- Gregory Brunin, M.D. Ophthalmology · San Antonio, TX
- Kyle M. Rhodes, MD Ophthalmology · Lakeway, TX
- Nolan Jepsen, O.D. Optometrists · Layton, UT
- James D. Paauw, M.D. Ophthalmology · Lynchburg, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Piedmont Eye Center Inc $432,072
- Eye Research Foundation $414,703
- R and R Eye Research LLC $348,815
- Global Research Management $342,951
- Visionary Research Institute $281,077
- Martel Eye Medical Group $248,760
- Oak City Eye Care Od PLLC $195,205
- Clayton Eye Clinical Research LLC $173,751
- Vision Research Institute, LLC $146,829
- Scott & Christie and Associates, PC $141,665
- Orange County Ophthalmology Medical Group $118,494
- Wesley Optometric Consulting LLC $112,395
- Kannarr Eye Care $96,604
- Revolution Research $94,895
- Cornea & Cataract Consultants of Arizona $93,314
- Total Practice Management $84,848
- Alpine Research Organization Inc. $70,723
- Moyes Eye Center PC $65,805
- North Bay Eye Associates $48,217
- Shettle Eye Research $45,074
- Advancing Vision Research $36,058
- Retina Associates Psc dba Butchertown Clinical Trials $32,344
- International Research Center $31,999
- Regents of the University of Colorado $22,830
- Eye Consultants of Atlanta PC $17,649
- Nature Coast Clinical Research $17,318
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.